Overview
Pramipexole is classified as a PCT (post-cycle therapy) and ancillary compound. Non-ergot dopamine D2/D3 receptor agonist.
With a half-life of ~8 hours, Pramipexole requires daily administration in most observed protocols. Taken orally, it has a bioavailability of approximately 90% via its primary route.
Half-life approximately 8 hours. Oral bioavailability ~90%. Shorter half-life than cabergoline. One-compartment model.
Mechanism of Action
Pramipexole's pharmacological activity involves the following key pathways:
Dopamine Receptor Agonism
Pramipexole activates dopamine D2 receptors in the pituitary, which inhibits prolactin secretion from lactotroph cells.
Prolactin Suppression
By stimulating dopamine receptors, Pramipexole reduces circulating prolactin levels in a dose-dependent manner.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
0.125 mg/day
Route
Oral
Frequency
Once daily
Duration
4-8 weeks
Dose
0.5 mg/day
Route
Oral
Frequency
Once daily
Duration
4-8 weeks
Frequently Asked Questions
What is pramipexole and how does it work?
Pramipexole is a non-ergot dopamine agonist with preferential affinity for the D3 receptor subtype (approximately 8 times higher than D2). It stimulates dopamine receptors in the brain, which suppresses prolactin secretion from the pituitary gland. FDA-approved for Parkinson’s disease and restless legs syndrome, it is also used in bodybuilding contexts for prolactin management alongside 19-nor compounds.
What is the half-life of pramipexole?
Pramipexole has a terminal half-life of approximately 8 hours in healthy adults (up to 12 hours in older individuals). This shorter half-life compared to cabergoline means daily dosing is required to maintain consistent blood levels. Steady-state concentrations are typically reached within 2 days of regular dosing. The absolute bioavailability is greater than 90%.
How does pramipexole compare to cabergoline?
Both compounds effectively lower prolactin, but differ in several key areas. Pramipexole has a shorter half-life (8 hours vs 63–69 hours) requiring daily dosing instead of twice weekly. Pramipexole has higher D3 selectivity and does not carry the cardiac valvulopathy concern associated with cabergoline’s 5-HT2B activity. Pramipexole has also been observed to increase growth hormone levels in a dose-dependent manner. It is typically less expensive and has fewer counterfeit products in circulation.
Why is slow titration important with pramipexole?
Pramipexole requires gradual dose escalation over 2–3 weeks to minimize side effects. Starting at a low dose (0.125 mg/day) and increasing incrementally allows the body to adapt to increased dopaminergic stimulation. Jumping directly to a full dose is commonly associated with pronounced nausea, dizziness, and excessive drowsiness. Bedtime dosing is frequently observed as it allows users to sleep through the initial side effects.
What are the common side effects of pramipexole?
The most commonly reported side effects include drowsiness and sedation (due to dopaminergic suppression of arousal pathways), nausea (especially during titration), orthostatic hypotension (lightheadedness when standing quickly), and dry mouth. At higher doses, vivid dreams or mild hallucinations have been reported. Unlike cabergoline, pramipexole does not carry the cardiac valve concern as it lacks significant 5-HT2B receptor activity.
Does pramipexole affect growth hormone levels?
Clinical observations have shown that pramipexole can increase growth hormone secretion in a dose-dependent manner, an effect attributed to its D3 receptor agonism. This is considered an additional benefit in bodybuilding contexts, distinguishing it from cabergoline which does not share this property. The GH-elevating effect is more pronounced at higher doses.